JP7628512B2 - ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体 Download PDF

Info

Publication number
JP7628512B2
JP7628512B2 JP2021575482A JP2021575482A JP7628512B2 JP 7628512 B2 JP7628512 B2 JP 7628512B2 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP 7628512 B2 JP7628512 B2 JP 7628512B2
Authority
JP
Japan
Prior art keywords
mmol
stirred
methyl
reaction
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537047A5 (https=
JP2022537047A (ja
JPWO2020254985A5 (https=
Inventor
エリック、ピー．ギリス
クリスティアナ、イワグウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022537047A publication Critical patent/JP2022537047A/ja
Publication of JP2022537047A5 publication Critical patent/JP2022537047A5/ja
Publication of JPWO2020254985A5 publication Critical patent/JPWO2020254985A5/ja
Application granted granted Critical
Publication of JP7628512B2 publication Critical patent/JP7628512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021575482A 2019-06-19 2020-06-17 ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体 Active JP7628512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (4)

Publication Number Publication Date
JP2022537047A JP2022537047A (ja) 2022-08-23
JP2022537047A5 JP2022537047A5 (https=) 2023-06-21
JPWO2020254985A5 JPWO2020254985A5 (https=) 2023-06-21
JP7628512B2 true JP7628512B2 (ja) 2025-02-10

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575482A Active JP7628512B2 (ja) 2019-06-19 2020-06-17 ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体

Country Status (33)

Country Link
US (2) US12129255B2 (https=)
EP (1) EP3986561B1 (https=)
JP (1) JP7628512B2 (https=)
KR (1) KR102932817B1 (https=)
CN (2) CN119039288A (https=)
AR (1) AR119174A1 (https=)
AU (1) AU2020295793B2 (https=)
BR (1) BR112021025655A2 (https=)
CL (1) CL2021003388A1 (https=)
CO (1) CO2021017479A2 (https=)
CR (1) CR20210664A (https=)
DK (1) DK3986561T3 (https=)
ES (1) ES2974541T3 (https=)
FI (1) FI3986561T3 (https=)
HR (1) HRP20240501T1 (https=)
HU (1) HUE065762T2 (https=)
IL (1) IL288750B2 (https=)
LT (1) LT3986561T (https=)
MA (1) MA56526B1 (https=)
MD (1) MD3986561T2 (https=)
MX (1) MX2021016149A (https=)
MY (1) MY206712A (https=)
PE (1) PE20220510A1 (https=)
PH (1) PH12021553180A1 (https=)
PL (1) PL3986561T3 (https=)
PT (1) PT3986561T (https=)
RS (1) RS65304B1 (https=)
SI (1) SI3986561T1 (https=)
SM (1) SMT202400153T1 (https=)
TW (1) TWI850403B (https=)
UA (1) UA128967C2 (https=)
UY (1) UY38755A (https=)
WO (1) WO2020254985A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521460A (ja) * 2020-04-15 2023-05-24 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルス複製の阻害剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
WO2020254559A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20220347174A1 (en) * 2019-10-01 2022-11-03 Viiv Healthcare Company Method for treating HIV with Cabotegravir and Rilpivirine
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IL157029A0 (en) 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
EP3507288B1 (en) * 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521460A (ja) * 2020-04-15 2023-05-24 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7799620B2 (ja) 2020-04-15 2026-01-15 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤

Also Published As

Publication number Publication date
EP3986561B1 (en) 2024-02-14
JP2022537047A (ja) 2022-08-23
SI3986561T1 (sl) 2024-04-30
MA56526A (fr) 2022-04-27
BR112021025655A2 (pt) 2022-02-01
FI3986561T3 (fi) 2024-05-02
MY206712A (en) 2025-01-03
CN119039288A (zh) 2024-11-29
KR20220024608A (ko) 2022-03-03
IL288750B2 (en) 2025-04-01
UY38755A (es) 2020-11-30
SMT202400153T1 (it) 2024-05-14
AU2020295793B2 (en) 2023-07-06
PL3986561T3 (pl) 2024-06-10
EP3986561A1 (en) 2022-04-27
AU2020295793A1 (en) 2022-01-20
PH12021553180A1 (en) 2022-11-07
CR20210664A (es) 2022-01-21
HRP20240501T1 (hr) 2024-07-05
DK3986561T3 (da) 2024-03-04
TW202115055A (zh) 2021-04-16
MD3986561T2 (ro) 2024-06-30
MX2021016149A (es) 2022-05-18
UA128967C2 (uk) 2024-12-11
AR119174A1 (es) 2021-12-01
CO2021017479A2 (es) 2022-04-19
WO2020254985A1 (en) 2020-12-24
IL288750B1 (en) 2024-12-01
US12129255B2 (en) 2024-10-29
CL2021003388A1 (es) 2022-09-30
HUE065762T2 (hu) 2024-06-28
IL288750A (en) 2022-02-01
CN114245795B (zh) 2024-08-06
RS65304B1 (sr) 2024-04-30
MA56526B1 (fr) 2024-05-31
CN114245795A (zh) 2022-03-25
LT3986561T (lt) 2024-04-25
PT3986561T (pt) 2024-03-15
US20250019383A1 (en) 2025-01-16
PE20220510A1 (es) 2022-04-07
CA3143136A1 (en) 2020-12-24
KR102932817B1 (ko) 2026-03-04
TWI850403B (zh) 2024-08-01
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27

Similar Documents

Publication Publication Date Title
JP7628512B2 (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体
EP3917930B1 (en) Inhibitors of human immunodeficiency virus replication
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
US20230106880A1 (en) Inhibitors of human immunodeficiency virus replication
IL296182A (en) Inhibitors of human immunodeficiency virus replication
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
CA3143136C (en) Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40066649B (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
HK40066649A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
BR122024007306A2 (pt) Composição farmacêutica que compreende o composto da fórmula ia, fórmula ib, fórmula ic ou fórmula id e uso da mesma para tratamento de infecção por hiv

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250129

R150 Certificate of patent or registration of utility model

Ref document number: 7628512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150